Spero Therapeutics, Inc. (NASDAQ:SPRO) CFO Sells $16,137.42 in Stock

Spero Therapeutics, Inc. (NASDAQ:SPRO) CFO Esther Rajavelu sold 20,689 shares of the stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $0.78, for a total value of $16,137.42. Following the completion of the sale, the chief financial officer now directly owns 724,720 shares of the company’s stock, valued at approximately $565,281.60. This represents a 2.78 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Spero Therapeutics Stock Performance

Spero Therapeutics stock opened at $0.82 on Friday. The company’s 50 day simple moving average is $0.99 and its 200-day simple moving average is $1.19. Spero Therapeutics, Inc. has a 1 year low of $0.74 and a 1 year high of $1.89. The company has a market capitalization of $44.62 million, a price-to-earnings ratio of 11.69 and a beta of 0.61.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on SPRO. TD Cowen restated a “hold” rating on shares of Spero Therapeutics in a report on Monday, November 18th. Evercore ISI lowered shares of Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price objective for the company. in a report on Friday, December 20th. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Spero Therapeutics in a research note on Thursday, January 30th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Spero Therapeutics in a research note on Friday, November 15th.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.